Stammdaten
Unternehmen
| Name | RECURSION PHARMACEUTICALS, INC. |
|---|---|
| Ticker | RXRX |
| CIK | 0001601830 |
Branche
| SIC-Code | 2836 |
|---|---|
| Beschreibung | Biological Products, (No Diagnostic Substances) |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | RECURSION PHARMACEUTICALS, INC. |
Status
| Zuletzt geprüft | 2026-03-20 22:35:49.690894 |
|---|
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Khan Najat | Director, Officer, CEO and President | Open Market Sale | -28,298 | 3.35 | -94,659.64 | -20,3% | |
| 2026-03-03 | Borgeson Blake | Director | Open Market Sale | -170,000 | 3.46 | -588,200.00 | -126,0% | |
| 2026-02-19 | Gibson Christopher | Director | Open Market Sale | -40,000 | 3.46 | -138,400.00 | -29,6% | |
| 2026-02-18 | Taylor Ben R | Officer, Chief Financial Officer | Open Market Sale | -13,426 | 3.08 | -41,352.08 | -8,9% | |
| 2026-02-04 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.12 | -164,800.00 | -35,3% | |
| 2026-02-03 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.20 | -924,000.00 | -197,9% | |
| 2026-01-20 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.47 | -178,800.00 | -38,3% | |
| 2026-01-06 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.36 | -959,200.00 | -205,5% | |
| 2026-01-05 | Gibson Christopher | Director | Open Market Sale | -40,000 | 4.25 | -170,000.00 | -36,4% | |
| 2025-12-29 | Taylor Ben R | Officer, Chief Financial Officer | Open Market Sale | -21,383 | 4.18 | -89,380.94 | -19,1% | |
| 2025-12-22 | Khan Najat | Director, Officer, Chief R&D Commercial Officer | Open Market Sale | -124,403 | 4.41 | -548,592.35 | -117,5% | |
| 2025-12-19 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.50 | -180,000.00 | -38,6% | |
| 2025-12-04 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.63 | -185,200.00 | -39,7% | |
| 2025-12-02 | Borgeson Blake | Director | Open Market Sale | -220,000 | 4.37 | -961,400.00 | -206,0% | |
| 2025-11-19 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 4.16 | -166,400.00 | -35,6% | |
| 2025-11-04 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -40,000 | 5.21 | -208,400.00 | -44,6% | |
| 2025-10-23 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 5.70 | -570,000.00 | -122,1% | |
| 2025-10-10 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 6.04 | -604,000.00 | -129,4% | |
| 2025-09-25 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.76 | -476,000.00 | -102,0% | |
| 2025-09-10 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.71 | -471,000.00 | -100,9% | |
| 2025-08-26 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 4.84 | -484,000.00 | -103,7% | |
| 2025-08-18 | Khan Najat | Director, Officer, Chief R&D Commercial Officer | Open Market Sale | -36,599 | 5.52 | -202,172.88 | -43,3% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -500,300 | 5.28 | -2,641,584.00 | -565,9% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -100,000 | 5.28 | -528,000.00 | -113,1% | |
| 2025-08-11 | Gibson Christopher | Director, Officer, Chief Executive Officer | Open Market Sale | -17,875 | 5.28 | -94,380.00 | -20,2% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.